<SUBMISSION>
<ACCESSION-NUMBER>0001104659-06-000195
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>5
<PERIOD>20051230
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20060104
<DATE-OF-FILING-DATE-CHANGE>20060103
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>CERUS CORP
<CIK>0001020214
<ASSIGNED-SIC>2836
<IRS-NUMBER>680262011
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-21937
<FILM-NUMBER>06503762
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>2411 STANWELL DR
<CITY>CONCORD
<STATE>CA
<ZIP>94520
<PHONE>9252886000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>2525 STANWELL DRIVE
<STREET2>STE 300
<CITY>CONCORD
<STATE>CA
<ZIP>94520
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>CERUS TECHNOLOGIES INC
<DATE-CHANGED>19960731
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a06-1064_18k.htm
<DESCRIPTION>CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border:none;border-top:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE
COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT<br>
Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the<br>
Securities Exchange Act of 1934</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):&#160; <b><font style="font-weight:bold;">December&nbsp;30, 2005</font></b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CERUS CORPORATION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-21937</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">68-0262011</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State of jurisdiction)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File No.)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer Identification No.)</font></p>
  </td>
 </tr>
</table>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2411 Stanwell Drive</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Concord, California 94520</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices and zip code)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: <b><font style="font-weight:bold;">(925) 288-6000</font></b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425
under the Securities Act (17 CFR 230.425)</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12
under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
the Exchange Act (17 CFR 240.13e-4(c))</p>

<div style="border:none;border-bottom:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kmuthiah\06-1064-1\task732866\1064-1-ba.htm',USER='kmuthiah',CD='Jan  4 03:29 2006' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Other Events.</b></p>

<p align="left" style="margin:0in 0in .0001pt 1.0in;text-align:left;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">On December&nbsp;30, 2005, Cerus
Corporation (the &#147;Company&#148;) announced that it has submitted a CE Mark
application for approval to market its INTERCEPT Blood System for plasma in
Europe.&#160; </font>A copy of the Company&#146;s
press release, entitled &#147;Cerus Submits CE Mark Application for European
Approval of the INTERCEPT Blood System for Plasma,&#148; is furnished as Exhibit&nbsp;99.1
hereto.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, on December&nbsp;30, 2005, the Company
announced that it has submitted an investigational new drug application to the
U.S. Food and Drug Administration to initiate a Phase 1 safety trial for CRS-100,
a <i><font style="font-style:italic;">Listeria</font></i>-based immunotherapeutic
designed to treat patients with cancer that has metastisized to the liver.&#160; A copy of the Company&#146;s press release,
entitled &#147;Cerus Submits IND Application for CRS-100 to FDA,&#148; is furnished as Exhibit&nbsp;99.2
hereto.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Financial
Statements and Exhibits.</b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Exhibits</b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Press
Release, dated December&nbsp;30, 2005, entitled &#147;Cerus Submits CE Mark
Application for European Approval of the INTERCEPT Blood System for Plasma.&#148;</p>

<p align="left" style="margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-align:left;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Press
Release, dated December&nbsp;30, 2005, entitled &#147;Cerus Submits IND Application
for CRS-100 to FDA.&#148;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\kmuthiah\06-1064-1\task732866\1064-1-ba.htm',USER='kmuthiah',CD='Jan  4 03:29 2006' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.92%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:49.08%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERUS CORPORATION</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.92%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.92%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.92%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:&nbsp;&nbsp;&nbsp;January&nbsp;3, 2006</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="30%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.64%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;/s/ Howard G. Ervin</font></p>
  </td>
  <td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.6%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.92%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Howard G. Ervin</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.92%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President, Legal Affairs</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\kmuthiah\06-1064-1\task732866\1064-1-ba.htm',USER='kmuthiah',CD='Jan  4 03:29 2006' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="6%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:6.94%;">
  <p style="margin:0in 0in .0001pt;text-align:justify;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>
  Number</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="90%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:90.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:6.94%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="90%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:90.82%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.94%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="90%" valign="top" style="padding:0in 0in 0in 0in;width:90.82%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release, dated December&nbsp;30, 2005,
  entitled &#147;Cerus Submits CE Mark Application for European Approval of the
  INTERCEPT Blood System for Plasma.&#148;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.94%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="90%" valign="top" style="padding:0in 0in 0in 0in;width:90.82%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.94%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.2</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="90%" valign="top" style="padding:0in 0in 0in 0in;width:90.82%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release, dated December&nbsp;30, 2005,
  entitled &#147;Cerus Submits IND Application for CRS-100 to FDA.&#148;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\kmuthiah\06-1064-1\task732866\1064-1-ba.htm',USER='kmuthiah',CD='Jan  4 03:29 2006' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a06-1064_1ex99d1.htm
<DESCRIPTION>EXHIBIT 99
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.1</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="153" height="57" src="g10641mmi001.jpg"></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contacts:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ruey-Li Hwang</font></p><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Communications</font></p><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus Corporation</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(925) 288-6017</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="font-weight:bold;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERUS SUBMITS CE
MARK APPLICATION FOR EUROPEAN APPROVAL OF<br>
THE INTERCEPT BLOOD SYSTEM FOR PLASMA</font></b></p>

<p align="center" style="font-weight:bold;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONCORD, CA, December&nbsp;30, 2005 - Cerus
Corporation (NASDAQ: CERS) announced today the submission of a CE Mark
application for approval to market the INTERCEPT Blood System for plasma in
Europe.&#160; The system, which is being
jointly developed by Cerus and Baxter Healthcare Corporation, is designed to
reduce the risk of transfusion-transmitted diseases. It inactivates pathogens
such as HIV, hepatitis B and C viruses, bacteria, and parasites that may be
present in donated plasma intended for transfusion.</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">&#147;We believe in pathogen
inactivation and its potential to improve the safety of the global blood
supply,&#148;</font> said Claes Glassell, president and CEO of Cerus Corporation. &#147;This
filing is one more step in our plan to commercialize the INTERCEPT Blood System
for all three components: platelets, plasma, and red blood cells.&#148;</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">While donated plasma is generally tested for a limited
number of specific pathogens, testing does not eliminate the risk of viral or
bacterial contamination. The INTERCEPT Blood System for plasma is being
developed to enhance the safety of plasma transfusions by targeting the nucleic
acids of a broad spectrum of viruses, bacteria and other pathogens.</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h5 style="color:black;font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-autospace:none;"><b><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">ABOUT THE INTERCEPT BLOOD SYSTEM</font></b></h5>

<h5 style="color:black;font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;text-autospace:none;"><b><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></b></h5>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus Corporation is collaborating with subsidiaries
of Baxter International Inc. on the INTERCEPT Blood System, designed to target
and inactivate blood-borne pathogens, such as HIV and hepatitis B and C, as
well as harmful white blood cells, while leaving intact the therapeutic
properties of donated blood components. Based on Cerus&#146; Helinx technology, the
INTERCEPT Blood System inactivates a broad array of pathogens and offers the
potential to inactivate untested-for and emerging pathogens before they become
a major transfusion risk to patients. The INTERCEPT Blood System for plasma has
been evaluated in three Phase III clinical trials, and a CE Mark application
for approval in Europe has</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kmuthiah\06-1064-1\task732866\1064-1-mm.htm',USER='kmuthiah',CD='Jan  4 03:25 2006' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">been submitted. The INTERCEPT Blood System for
platelets is approved for use in the European Union.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h4 style="color:black;font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;"><b><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">ABOUT CERUS</font></b></h4>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus Corporation
is developing novel products for cancer, infectious disease and blood safety
based on multiple, innovative technology platforms. The company is building a
pipeline of next generation cancer immunotherapies by combining its proprietary
attenuated <i><font style="font-style:italic;">Listeria</font></i> vector platform with promising
disease antigens. These products are designed to stimulate innate and T cell
immune pathways, generating highly potent anti-tumor responses. The company&#146;s
KBMA vaccine technology has potential broad applications against multiple
pathogens. Cerus is applying its Helinx technology to develop the INTERCEPT
Blood System, which is designed to enhance the safety of blood components
through pathogen inactivation. The company&#146;s strategy is to leverage the broad
potential of its technologies and products through alliances. Cerus&#146; partners to
date include MedImmune and Johns Hopkins University for cancer immunotherapy,
and Baxter International and BioOne Corporation for the INTERCEPT Blood System.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Helinx is a trademark of Cerus Corporation.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Baxter and INTERCEPT are
trademarks of Baxter International,&nbsp;Inc.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-weight:bold;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:normal;">Statements in this news release
regarding potential efficacy and safety of products, product development and
commercial potential are forward-looking statements that involve risks and
uncertainties.&#160; Actual results could
differ materially from the above forward-looking statements as a result of
certain factors, including the risks and uncertainties inherent in developing
biotechnology products based on new technologies, the timing and results of
clinical trials and other development activities, market acceptance of Cerus
Corporation&#146;s products, actions by regulatory authorities at any stage of the
development process, the availability of governmental or third party reimbursement
for the use of Cerus Corporation&#146;s products, the size of the market for the
company&#146;s products, competitive conditions, manufacturing capabilities, and
other factors discussed in the company&#146;s Form&nbsp;10Q for the third quarter of
fiscal 2005, as well as in other reports filed with the Securities and Exchange
Commission. The company assumes no obligation to update any forward-looking statements.</font></i></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:normal;">###</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kmuthiah\06-1064-1\task732866\1064-1-mm.htm',USER='kmuthiah',CD='Jan  4 03:25 2006' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>a06-1064_1ex99d2.htm
<DESCRIPTION>EXHIBIT 99
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.2</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="153" height="57" src="g10641moi001.gif" alt="GRAPHIC"></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contact:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ruey-Li Hwang</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate
Communications</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus Corporation</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(925) 288-6017</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="font-weight:bold;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERUS SUBMITS IND
APPLICATION FOR CRS-100 TO FDA</font></b></p>

<p align="center" style="font-weight:bold;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONCORD, CA, December&nbsp;30, 2005 - Cerus
Corporation (NASDAQ: CERS) today announced that it has submitted an
investigational new drug (IND) application to the U.S. Food and Drug
Administration (FDA) to initiate a Phase 1 safety trial for CRS-100, a <i><font style="font-style:italic;">Listeria</font></i>-based immunotherapeutic designed
to treat patients with cancer that has metastasized to the liver.</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preclinical
studies demonstrate the potential of Cerus&#146; proprietary </font><em><i><font face="Times New Roman">Listeria</font></i></em> strain (CRS-100) to stimulate a potent immune response against certain
cancers in the liver. Data from some of these studies have been published in
peer-reviewed journals, including a paper in the September&nbsp;21, 2004, issue
of the <i><font style="font-style:italic;">Proceedings of the National Academy
of Sciences</font></i>. Subject to FDA concurrence, Cerus intends to initiate a
Phase I clinical trial in collaboration with investigators at leading cancer
centers in the United States during the first half of 2006.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">&#147;The filing of our first IND
in cancer immunotherapy using our proprietary <i><font style="font-style:italic;">Listeria</font></i>
platform is an important milestone in Cerus&#146; strategic development</font>,&#148;
said Claes Glassell, president and CEO of Cerus Corporation. &#147;</font>We believe that our <i><font style="font-style:italic;">Listeria </font></i>platform will lead to more potent
and effective therapies that stimulate both innate and adaptive immune
responses to target cancer cells. I am
very proud of the remarkable progress our team has recently made on our
immunotherapy programs.&#148;</p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Colorectal cancer, which is
the second most common cause of cancer death in the United States, often
metastasizes to the liver, contributing to its morbidity. Despite recent
advances, metastasized colorectal cancer remains a significant unmet medical
need.</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABOUT CERUS</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus Corporation
is developing novel products for cancer, infectious disease and blood safety
based on multiple, innovative technology platforms. The company is building a
pipeline of next generation cancer immunotherapies by combining its proprietary
attenuated <i><font style="font-style:italic;">Listeria</font></i> vector platform with promising
disease antigens. These products are designed to stimulate innate and T cell
immune pathways, generating highly potent anti-tumor responses. Cerus is
applying its Helinx technology to develop the INTERCEPT</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kmuthiah\06-1064-1\task732866\1064-1-mo.htm',USER='kmuthiah',CD='Jan  4 03:27 2006' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Blood System,
which is designed to enhance the safety of blood components through pathogen
inactivation. The company&#146;s strategy is to leverage the broad potential of its
technologies and products through alliances. Cerus&#146; partners to date include
MedImmune and Johns Hopkins University for cancer immunotherapy, and Baxter
International and BioOne Corporation for the INTERCEPT Blood System.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-weight:bold;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:normal;">Statements in this news release
are forward-looking statements that involve risks and uncertainties, including
statements concerning the potential safety and efficacy of product candidates
and the potential of the company&#146;s Listeria based immunotherapy
technology.&#160; Actual results could differ
materially from the above forward-looking statements as a result of certain
factors, including the risks and uncertainties inherent in developing
biotechnology products based on new technologies, the timing and results of
clinical trials and other development activities, market acceptance of our
products, actions by regulatory authorities at any stage of the development
process, the availability of governmental or third party reimbursement for the
use of our products, the size of the market for our products, competitive
conditions, manufacturing capabilities, our reliance on our relationship with
partners and other factors discussed in the company&#146;s Form&nbsp;10-Q for the
third quarter of fiscal 2005, as well as in other reports filed from time to
time with the Securities and Exchange Commission. The company assumes no obligation
to update any forward-looking statements.</font></i></b></p>

<p align="left" style="font-weight:bold;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="font-weight:bold;line-height:normal;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:normal;">###</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kmuthiah\06-1064-1\task732866\1064-1-mo.htm',USER='kmuthiah',CD='Jan  4 03:27 2006' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g10641mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10641mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"``Y`)D#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V6BH[BXAM
M+>2XN94AAC4L\CL`JCU)-<BOCF^UF1T\*^'Y]1A4E3>3N((<^V>6^G!H`[*B
MN0>]^(:+Y@TC19!G_5+</NQZ9.!6='\2M0LM9MM(U[PQ-8W%Q(L:NLVY6R0,
MCC!'/8F@#T"BLG4M>33;P0/;EP5#;@V/7MCVJK_PEMO_`,^LGYBN26-P\).,
MI:KU.F.$KRBI*.C.@HKG_P#A+;?_`)]9/S%3V/B)+Z^CM4MF7?GYBW3`)Z8]
MJ4<=AY-14M7ZC>#KQ3;CHC9HKGK[7M?@U*>ULO"<]Y#$1MN/M<<:OP#P&^N/
MPK*?XEV^F:@EEXBT:]T=Y/NR/B2/Z[EZCZ`UV'*=M147G>;:>?:E)]R;HL/A
M7XR/F&>#Z\UQ&K_$JYT76UT:[\.R&[D*"(1W099-QP,':.]`'>45!9R7,MNK
MW=NEO*>L:2^8!^.!_*I9"XB<Q*'<*=JLVT$]@3@X_*@!U%<7>^/;^Q\20^'Y
MO#C&^N-IAV78*.IS\V=O`&#V[&N@U37[30-'_M'672U``!1&WDM_=7@;C^'Z
M4`:E%<C;^)O$^K0"YTOPJ([9QF*2^NQ&SCL=@!(_.J6H^.O$.A31#6/")2&9
MQ&D\%V'7<3C'"_H<4`=W1110!YEXRO)?%OCJQ\%02LEE$PEO2A^^0N['X+C'
MNWM7I%K;065K':VT2Q0Q*%1$&`H':O)_!;F7XT:XTA#,'N@I/;$@`Q^`KUV@
M`K(\1:.-6@LF6-7FL[^WN(R>-H61=_\`XYNK7HH`KS6-I<2^;-;QR/C&67/%
M)_9MA_SY6_\`WZ7_``K*UC6KO3]0$$"1NIC#8923G)]#58>)-2(R+%3_`,`:
MO.GB\-&;C):KR.^&&Q$H*2>GJ;W]FV'_`#Y6_P#WZ7_"B/3[.&99HK:*-USA
ME4#%87_"1ZE_SX+_`-\-4FF:]>WFIPVTT<2(^[.U2#P">Y]J4<7A7)12U;[#
MEA<0HMMZ+S.BKE/B7I4.I^"+]I(P9;1//B?NI7K^:Y%=#J&IV.DP"?4+J*UB
M9MHDE;:N?3/X5Q?C'Q'!XCTF3P[X88:G>WI5)&@&Z."/.2S/T&<8KTCSR?X1
MW,]QX&B69BP@GDCC)_N\''YDUS/Q"A#?%WP^H.#*+7)_[;L/Z5Z-X5T%/#7A
MVUTM7#M$I,CCHSDY8_3)X]@*\]\??\EA\-?]NO\`Z4-0,]9HHHH$>;^(O^2X
M>'_^O/\`K-67\9I9H=;T66:/S+-%9@AZ,P8;AZ=-M:GB+_DN'A__`*\_ZS5V
M/B7PW8>*=)?3[Y2!G='*OWHV[$?X4#+>DZM8ZWIT5_I\ZS02#@CJI]".Q'I3
MM1T^WU2R>TNE)B=E8XZY5@P/Y@5X==:;XM^%^IFZMI&-JS8\Y`6@E'8.O8_7
MGK@]Z]+\%_$33_%8%K*HM-2"Y,!.5DQU*'O].H]\9H`["BBB@1XKKDC^!_B\
M-5D1A9W,GG$@?>208?\`$')Q["O9XI8YHDEB=7C=0RLIR&!Z$5B>+O"5EXNT
MK[)<GRIHR6@G49,;?U![C_"N#TC4?&'PYSI^J:5-J>DH3Y<MOE_+'^RV.!_L
MMC\*!GK5,FFBMXC+-(L<:]6<X`_&N,B^+?A1XRTLUU;N.L<ENVX'TXR/UK/G
M\8R>-=5T_2=#TZ[.G_:XY;R[EB(4HC!]HQT!VCDD>F*!'HU%8.L?VO\`VB/L
M'F^7L'W?NYR?6JO_`!4__33_`,<KAGC>23CR2=NR.R.$YHJ7.E?NSJ**Y?\`
MXJ?_`*:?^.5-IIUO^U(?MOG>3\V[.-OW3CI[THXWFDH^SDK]T.6$M%OGCIYF
MQJ>FVNL:;/I][$)+>=-KK_4>A!Y!]17DFD7U]\*?%<FE:F6ET>\;<LH'&.@D
M`]1T8?SXKV6LCQ-X:L?%.DO87RD?Q12K]Z)^Q'^'>N\XC4AFCN(4FAD62*10
MR.IR&!Y!%>2?%4FP\?Z%JLF1"D<?/^Y*6/Z,*L:#?>)/AQ>?V3K%C<7^C,Q\
MJXMD,@B]QZ#U4X[D>^_XEL]$^)&C"TT_4(_MT.9;=F5E*GN&4C.#^G![8H&=
ML""`0<@]Z6O.=`\6ZSX7LDTGQ7HE_BV79%>V\1E5E'0,1QP.X_$=ZUI_'QO4
M,/AS1-1U*Y<?(SP&*%3ZLS8P/\Y%`C*NP-2^.MD(P&&FV!\WCIE7Q^LJUZ$D
MT<CR(DBL\9`=0<E21D`^G!!KFO!WA:XT4WFIZK.MSJ^I/ON)%^Z@[(OM_P#6
M]!6'J.MZWX4\=ZK=R:)>7NC7WDMYEO'N*%8U4D8XZ@C!QTH&>@S0Q7$+PSQI
M+$XVNCJ"K#T(/6O#?B+X63P9KEGJ6C2-!#<,7B4')AD4@\>W(Q^->D)\2=#E
MC)CM]3>4<&!;)RX/ITQ^M8=[H>L_$77;2ZU33Y-)T.R)*0S\3S9QG*_PYP!S
MT[9H`]`TVY>\TRUNI%VO-"DC+Z$J#C]:LTBJ%4*H``&`!VI:!!1110`4444`
C%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g10641moi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10641moi001.gif
M1TE&.#EAF0`Y`/4``,C'QUE65Y".C_WCQ_'Q\?O&CS`L+75S<TQ(2:RJJ^/C
MXX.!@?FJ5[JXN=75U6=E93XZ.YZ<G?[X\?JY<_S4J_WJU?[QX_B<._JQ9?O`
M@?FC2?O-G?B5+?S<N?>.'R(>'____P``````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````"'_"TU33T9&24-%.2XP&`````QM
M<T]035-/1D9)0T4Y+C!`:4N4*@`A_PM-4T]&1DE#13DN,!@````,8VU04$I#
M;7`P-S$R`````T@`<[P`+`````"9`#D```;_0)!P2"P:C\BD<LEL.I_0J'1*
MK5JOV*QVR^UZO^"P>$PNF\_HM'K-;KO?\+A\3J_;[_C\F@`0"`*`@`]^``IZ
M;P``#0(-B0!7!!$('Y25EI8&`0L"AB`#'AH,$P6DI::GIA@,%QY##H&P`0(1
M#DJQ!PNP#4P/L`N]@+M%"@N3EY80FE$$`@:5"`>,C@+%QQ^/GA[:V]S=WMY#
M`-;("4@.?<Z5!@G82PH`$>D?!@(`!$0$!Y40@WZY\A\"0'$`@1*]3D@B%:R$
M[=.WAQ"U#5$@;6("8Y00W$,BP%($*0TJ+3#B(!T"848:&!/H)('(C4TZ4FH8
ML28X)A$L:40BCN$4_Y]$2E)Z`!.)/@$M*Y6+XO+#1H<VHR85R=-2.RA`AQ@S
M4#3A!Z1,'%3Z."7`AR$6"FP8,$!"%`ML23UY8`DAD9XS?^8=$I+2R":#F!!8
M^*"*2S<*/!Y)G!7K7B$RO[9<JD2F`;M1$K_!R-*(5;W7B)BE!#8+XP]_JYQU
MLZ!2YR*6NCII//H#A"VM*6&6<N!-Y-=$+%%I'/D#62SI;A]B@A?X$.&@K_95
MBF5Z[^5+\*:&76GX8R$+*UVODELR]LICD4"7TAC$]&>UJ-2^>MY(^?B>NT<W
MHN]8Z2B?;2$!!6U5`1<%4"R$0!+K`?C=$/U=@@!]302H!53:A,+`AAQVV/\A
M*]P\@1=*^5'B76A'%&?)`;(I86$6&$85T1/&C'=$@XZA>$0#`*E#XA(O8A&C
MC`\YT9^--^K'WH-%$$"7-=NYV-X50Q)Y$Q$*L#/-0O^IIZ2#.B;!HS4[`4G=
M%@YQP&$&J+0Y`8?;'%&;>+LE:>)^@D6H4XM$R!/E%1)4`.,1!`"$'Q-UX=D$
M`.$]PZ<0M2U8'UX?2%KAE)=^4&<23OJG1'F:U@="<4@RB"FB=T:A8JA(O-?E
M<D]20IF43(;U)11-I9>$/,K51P!&'_QX!$:O,D>)<W.MJ(2>Q>JA@#P&''I$
MK*4R(5.U3IP6D!+:7E8%`8^&(98ZTA:1$R6])OO_P:SA#NO:$J`BZ\0F:^1J
MVZ/C4E*N$@144E0`%-I"%;^-8LL$`K.B86^9[E)B\!%-(0G!<4W4)BQ)ESR,
M1&+85,``FP2R)?+()(^\00%O/J$GPT78NR^AZ6#V@<;X[#-5)41!H<]35M:D
M\YY(1-JN$$_^J>^\E5S<*D`0*&V$2P8,467/<?[\3)V%7LWODY8&5^G+1)P[
M<Q0.`!M0PDWFUMG45+<2!:C1'D&0.F@+D<!"+-I)#Y\*Q/JG$\T<(XN6`"3P
MAR6EL4WU%&-6(H!LG:H332,"')".`11S9\G@B1B.$00!/\%,H^-@@I#'HQ10
M\NHD=T"**E3D<\D@C<`$1X#EI4/PN!*W]VC-`W53X4`$O8R3R0).(Q8!-;`\
L0"$\`O02#2T#&1X]('Y$$+JHW'?O_??@AR_^^.27;_[YZ*>O_OKLLQ\$`#L_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
